AtriCure Inc. (NASDAQ:ATRC) – Equities research analysts at Leerink Swann raised their Q4 2018 earnings per share estimates for shares of AtriCure in a research note issued on Thursday, January 17th. Leerink Swann analyst D. Antalffy now forecasts that the medical device company will post earnings per share of ($0.19) for the quarter, up from their prior forecast of ($0.20). Leerink Swann also issued estimates for AtriCure’s Q1 2019 earnings at ($0.24) EPS, Q4 2019 earnings at ($0.12) EPS, FY2019 earnings at ($0.38) EPS, Q1 2020 earnings at ($0.17) EPS, Q2 2020 earnings at $0.18 EPS, Q4 2020 earnings at ($0.04) EPS and FY2020 earnings at ($0.08) EPS.
Several other equities analysts also recently commented on ATRC. Needham & Company LLC boosted their price target on shares of AtriCure from $36.00 to $39.00 and gave the stock a “buy” rating in a research note on Thursday, October 4th. Canaccord Genuity boosted their price target on shares of AtriCure from $37.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, October 9th. Zacks Investment Research downgraded shares of AtriCure from a “buy” rating to a “hold” rating in a research note on Tuesday, October 23rd. Finally, BidaskClub downgraded shares of AtriCure from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, November 13th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. AtriCure currently has a consensus rating of “Buy” and a consensus price target of $35.60.
AtriCure (NASDAQ:ATRC) last posted its quarterly earnings results on Thursday, November 1st. The medical device company reported ($0.24) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.22) by ($0.02). The business had revenue of $49.90 million during the quarter, compared to analyst estimates of $49.90 million. AtriCure had a negative return on equity of 16.92% and a negative net margin of 10.41%. The business’s revenue was up 18.2% on a year-over-year basis. During the same quarter last year, the firm earned ($0.22) EPS.
Hedge funds have recently modified their holdings of the stock. Federated Investors Inc. PA acquired a new position in shares of AtriCure during the third quarter worth $34,000. Ibex Investors LLC acquired a new position in shares of AtriCure during the third quarter worth $204,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of AtriCure during the third quarter worth $210,000. Engineers Gate Manager LP acquired a new position in shares of AtriCure during the third quarter worth $521,000. Finally, Campbell & CO Investment Adviser LLC grew its stake in shares of AtriCure by 37.7% during the third quarter. Campbell & CO Investment Adviser LLC now owns 15,339 shares of the medical device company’s stock worth $537,000 after purchasing an additional 4,200 shares in the last quarter. Hedge funds and other institutional investors own 81.70% of the company’s stock.
AtriCure Company Profile
AtriCure, Inc provides atrial fibrillation solutions to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery.
Recommended Story: What is a Market Correction?
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.